Cytomegalovirus antivirals and development of improved animal models

Bibliography

• Gilbert C, Boivin G. Human cytomegalovirus resistance to antiviral drugs. Antimicrob Agents Chemother 2005;49(3):873-83
   PubMed Web of Science ®Google Scholar
• Ross SA, Boppana SB. Congenital cytomegalovirus infection: outcome and diagnosis. Semin Pediatr Infect Dis 2005;16(1):44-9
   PubMedGoogle Scholar
• Griffiths PD, Walter S. Cytomegalovirus. Curr Opin Infect Dis 2005;18(3):241-5
   PubMed Web of Science ®Google Scholar
• Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 2007;17(4):253-76
   PubMed Web of Science ®Google Scholar
• Colugnati FA, Staras SA, Dollard SC, Incidence of cytomegalovirus infection among the general population and pregnant women in the united states. BMC Infect Dis 2007;7:71
   PubMed Web of Science ®Google Scholar
• Fowler KB, Stagno S, Pass RF. Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA 2003;289(8):1008-11
   PubMed Web of Science ®Google Scholar
• Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol 2007;17(5):355-63
   PubMed Web of Science ®Google Scholar
• Pass RF. Immunization strategy for prevention of congenital cytomegalovirus infection. Infect Agents Dis 1996;5(4):240-4
   PubMedGoogle Scholar
• Caposio P, Orloff SL, Streblow DN. The role of cytomegalovirus in angiogenesis. Virus Res 2011;157(2):204-11
   PubMed Web of Science ®Google Scholar
• Streblow DN, Dumortier J, Moses AV, Mechanisms of cytomegalovirus-accelerated vascular disease: induction of paracrine factors that promote angiogenesis and wound healing. Curr Top Microbiol Immunol 2008;325:397-415
   PubMed Web of Science ®Google Scholar
• Soroceanu L, Cobbs CS. Is HCMV a tumor promoter? Virus Res 2011;157(2):193-203
   PubMed Web of Science ®Google Scholar
• Hahn G, Revello MG, Patrone M, Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol 2004;78(18):10023-33
   PubMed Web of Science ®Google Scholar
• Wang D, Shenk T. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc Natl Acad Sci USA 2005a;102(50):18153-8
   PubMed Web of Science ®Google Scholar
• Wang D, Shenk T. Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism. J Virol 2005b;79(16):10330-8
   PubMed Web of Science ®Google Scholar
• Ryckman BJ, Jarvis MA, Drummond DD, Human cytomegalovirus entry into epithelial and endothelial cells depends on genes UL128 to UL150 and occurs by endocytosis and low-pH fusion. J Virol 2006;80(2):710-22
   PubMed Web of Science ®Google Scholar
• Patrone M, Secchi M, Fiorina L, Human cytomegalovirus UL130 protein promotes endothelial cell infection through a producer cell modification of the virion. J Virol 2005;79(13):8361-73
   PubMed Web of Science ®Google Scholar
• Simanek AM, Dowd JB, Pawelec G, Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the united states. PLoS One 2011;6(2):e16103
   PubMed Web of Science ®Google Scholar
• Strandberg TE, Pitkala KH, Tilvis RS. Cytomegalovirus antibody level and mortality among community-dwelling older adults with stable cardiovascular disease. JAMA 2009;301(4):380-2
   PubMed Web of Science ®Google Scholar
• Sung H, Schleiss MR. Update on the current status of cytomegalovirus vaccines. Expert Rev Vaccines 2010;9(11):1303-14
   PubMed Web of Science ®Google Scholar
• Dolan A, Cunningham C, Hector RD, Genetic content of wild-type human cytomegalovirus. J Gen Virol 2004;85(Pt 5):1301-12
   PubMedGoogle Scholar
• Mocarski ES, Courcelle CT. Cytomegalovirus and their replication. In: Knipe DM, Howley PM. editors. Fields virology. 4th edition. Lippincott Williams and Wilkins; Philadelphia, PA: 2001. p. 2629-73
   Google Scholar
• Dargan DJ, Douglas E, Cunningham C, Sequential mutations associated with adaptation of human cytomegalovirus to growth in cell culture. J Gen Virol 2010;91(Pt 6):1535-46
   PubMedGoogle Scholar
• Macagno A, Bernasconi NL, Vanzetta F, Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol 2010;84(2):1005-13
   PubMed Web of Science ®Google Scholar
• Saccoccio FM, Sauer AL, Cui X, Peptides from cytomegalovirus UL130 and UL131 proteins induce high titer antibodies that block viral entry into mucosal epithelial cells. Vaccine 2011;29(15):2705-11
   PubMed Web of Science ®Google Scholar
• Razonable RR, Emery VC. 11th Annual Meeting of the IHMF (International Herpes Management Forum). Management of CMV infection and disease in transplant patients. Herpes 2004;11(3):77-86
   PubMedGoogle Scholar
• Sullivan V, Talarico CL, Stanat SC, A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 1992;358(6382):162-4
   PubMed Web of Science ®Google Scholar
• Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 2010;23(4):689-712
   PubMed Web of Science ®Google Scholar
• Chou S, Waldemer RH, Senters AE, Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. J Infect Dis 2002;185(2):162-9
   PubMed Web of Science ®Google Scholar
• Chou S. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev Med Virol 2008;18(4):233-46
   PubMed Web of Science ®Google Scholar
• Baldanti F, Michel D, Simoncini L, Mutations in the UL97 ORF of ganciclovir-resistant clinical cytomegalovirus isolates differentially affect GCV phosphorylation as determined in a recombinant vaccinia virus system. Antiviral Res 2002;54(1):59-67
   PubMed Web of Science ®Google Scholar
• Kimberlin DW, Lin CY, Sanchez PJ, Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr 2003;143(1):16-25
   PubMed Web of Science ®Google Scholar
• Whitley RJ, Cloud G, Gruber W, Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National institute of allergy and infectious diseases collaborative antiviral study group. J Infect Dis 1997;175(5):1080-6
   PubMed Web of Science ®Google Scholar
• Bradford RD, Cloud G, Lakeman AD, Detection of cytomegalovirus (CMV) DNA by polymerase chain reaction is associated with hearing loss in newborns with symptomatic congenital CMV infection involving the central nervous system. J Infect Dis 2005;191(2):227-33
   PubMed Web of Science ®Google Scholar
• Oliver SE, Cloud GA, Sanchez PJ, Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system. J Clin Virol 2009;46(Suppl 4):S22-6
   PubMed Web of Science ®Google Scholar
• Kimberlin DW. Antiviral therapy for cytomegalovirus infections in pediatric patients. Semin Pediatr Infect Dis 2002;13(1):22-30
   PubMedGoogle Scholar
• Morris DJ. Adverse effects and drug interactions of clinical importance with antiviral drugs. Drug Saf 1994;10(4):281-91
   PubMed Web of Science ®Google Scholar
• Faulds D, Heel RC. Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs 1990;39(4):597-638
   PubMed Web of Science ®Google Scholar
• Sharland M, Luck S, Griffiths P, Antiviral therapy of CMV disease in children. Adv Exp Med Biol 2011;697:243-60
   PubMed Web of Science ®Google Scholar
• Reusser P, Einsele H, Lee J, Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 2002;99(4):1159-64
   PubMed Web of Science ®Google Scholar
• Mattes FM, Hainsworth EG, Geretti AM, A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients. J Infect Dis 2004;189(8):1355-61
   PubMed Web of Science ®Google Scholar
• Luck S, Sharland M, Griffiths P, Advances in the antiviral therapy of herpes virus infection in children. Expert Rev Anti Infect Ther 2006;4(6):1005-20
   PubMedGoogle Scholar
• Wagstaff AJ, Bryson HM. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs 1994;48(2):199-226
   PubMed Web of Science ®Google Scholar
• Smith IL, Cherrington JM, Jiles RE, High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J Infect Dis 1997;176(1):69-77
   PubMed Web of Science ®Google Scholar
• Cihlar T, Fuller MD, Cherrington JM. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. J Virol 1998;72(7):5927-36
   PubMed Web of Science ®Google Scholar
• Chou S, Lurain NS, Thompson KD, Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J Infect Dis 2003;188(1):32-9
   PubMed Web of Science ®Google Scholar
• Biron KK. Antiviral drugs for cytomegalovirus diseases. Antiviral Res 2006;71(2-3):154-63
   PubMed Web of Science ®Google Scholar
• Bischofberger N, Hitchcock MJ, Chen MS, 1- [((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl] cytosine, an intracellular prodrug for (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine with improved therapeutic index in vivo. Antimicrob Agents Chemother 1994;38(10):2387-91
   PubMed Web of Science ®Google Scholar
• De Clercq E. Cidofovir in the treatment of poxvirus infections. Antiviral Res 2002;55(1):1-13
   PubMed Web of Science ®Google Scholar
• Bravo FJ, Stanberry LR, Kier AB, Evaluation of HPMPC therapy for primary and recurrent genital herpes in mice and guinea pigs. Antiviral Res 1993;21(1):59-72
   PubMed Web of Science ®Google Scholar
• Beadle JR, Hartline C, Aldern KA, Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob Agents Chemother 2002;46(8):2381-6
   PubMed Web of Science ®Google Scholar
• Ciesla SL, Trahan J, Wan WB, Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antiviral Res 2003;59(3):163-71
   PubMed Web of Science ®Google Scholar
• Kern ER, Collins DJ, Wan WB, Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir. Antimicrob Agents Chemother 2004;48(9):3516-22
   PubMed Web of Science ®Google Scholar
• Bravo FJ, Bernstein DI, Beadle JR, Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection. Antimicrob Agents Chemother 2011;55(1):35-41
   PubMed Web of Science ®Google Scholar
• Williams-Aziz SL, Hartline CB, Harden EA, Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro. Antimicrob Agents Chemother 2005;49(9):3724-33
   PubMed Web of Science ®Google Scholar
• Hartline CB, Gustin KM, Wan WB, Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro. J Infect Dis 2005;191(3):396-9
   PubMed Web of Science ®Google Scholar
• Hostetler KY. Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. Antiviral Res 2009;82(2):A84-98
   PubMed Web of Science ®Google Scholar
• Eriksson U, Peterson LW, Kashemirov BA, Serine peptide phosphoester prodrugs of cyclic cidofovir: synthesis, transport, and antiviral activity. Mol Pharm 2008;5(4):598-609
   PubMedGoogle Scholar
• Tehler U, Nelson CH, Peterson LW, Puromycin-sensitive aminopeptidase: An antiviral prodrug activating enzyme. Antiviral Res 2010;85(3):482-9
   PubMed Web of Science ®Google Scholar
• Peterson LW, Kim JS, Kijek P, Synthesis, transport and antiviral activity of ala-ser and val-ser prodrugs of cidofovir. Bioorg Med Chem Lett 2011;21(13):4045-9
   PubMed Web of Science ®Google Scholar
• Kern ER, Kushner NL, Hartline CB, In vitro activity and mechanism of action of methylenecyclopropane analogs of nucleosides against herpesvirus replication. Antimicrob Agents Chemother 2005;49(3):1039-45
   PubMed Web of Science ®Google Scholar
• Wu Z, Drach JC, Prichard MN, L-valine ester of cyclopropavir: a new antiviral prodrug. Antivir Chem Chemother 2009;20(1):37-46
   PubMedGoogle Scholar
• Borysko KZ, Gentry BG, Breitenbach JM, Resistacne of human cytomegalovirus to cyclopropavir involves a novel mutation in UL97. Antiviral Res 2008;78:A54
   Web of Science ®Google Scholar
• Tucker JA, Clayton TL, Chidester CG, Structure-activity relationships of acyloxyamidine cytomegalovirus DNA polymerase inhibitors. Bioorg Med Chem 2000;8(3):601-15
   PubMed Web of Science ®Google Scholar
• Vaillancourt VA, Cudahy MM, Staley SA, Naphthalene carboxamides as inhibitors of human cytomegalovirus DNA polymerase. Bioorg Med Chem Lett 2000;10(18):2079-81
   PubMed Web of Science ®Google Scholar
• Biron KK, Harvey RJ, Chamberlain SC, Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother 2002;46(8):2365-72
   PubMed Web of Science ®Google Scholar
• Krosky PM, Baek MC, Jahng WJ, The human cytomegalovirus UL44 protein is a substrate for the UL97 protein kinase. J Virol 2003;77(14):7720-7
   PubMed Web of Science ®Google Scholar
• Marschall M, Freitag M, Suchy P, The protein kinase pUL97 of human cytomegalovirus interacts with and phosphorylates the DNA polymerase processivity factor pUL44. Virology 2003;311(1):60-71
   PubMed Web of Science ®Google Scholar
• Prichard MN. Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir. Rev Med Virol 2009;19(4):215-29
   PubMed Web of Science ®Google Scholar
• Komazin G, Ptak RG, Emmer BT, Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27. J Virol 2003;77(21):11499-506
   PubMed Web of Science ®Google Scholar
• Chou S, Marousek GI, Senters AE, Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir. J Virol 2004;78(13):7124-30
   PubMed Web of Science ®Google Scholar
• Chou S. Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir. Antimicrob Agents Chemother 2009;53(1):81-5
   PubMed Web of Science ®Google Scholar
• Drew WL, Miner RC, Marousek GI, Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J Clin Virol 2006;37(2):124-7
   PubMed Web of Science ®Google Scholar
• Wang LH, Peck RW, Yin Y, Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 2003;47(4):1334-42
   PubMed Web of Science ®Google Scholar
• Chou S, Marousek GI. Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus. Antimicrob Agents Chemother 2006;50(10):3470-2
   PubMed Web of Science ®Google Scholar
• Winston DJ, Young JA, Pullarkat V, Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood 2008;111(11):5403-10
   PubMed Web of Science ®Google Scholar
• Marty FM, Ljungman P, Papanicolaou GA, Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis 2011;11(4):284-92
   PubMed Web of Science ®Google Scholar
• Uknis M. In: Prophylaxis against CMV with oral MBV in allogeneic stem cell transplant recipients: results of a randomized double blind placebo controlled trial. 12th international CMV/Betaherpesvirus workshop; Boston; 2009
   Google Scholar
• Marschall M, Stein-Gerlach M, Freitag M, Direct targeting of human cytomegalovirus protein kinase pUL97 by kinase inhibitors is a novel principle for antiviral therapy. J Gen Virol 2002;83(Pt 5):1013-23
   PubMedGoogle Scholar
• Herget T, Freitag M, Morbitzer M, Novel chemical class of pUL97 protein kinase-specific inhibitors with strong anticytomegaloviral activity. Antimicrob Agents Chemother 2004;48(11):4154-62
   PubMed Web of Science ®Google Scholar
• Zimmermann A, Wilts H, Lenhardt M, Indolocarbazoles exhibit strong antiviral activity against human cytomegalovirus and are potent inhibitors of the pUL97 protein kinase. Antiviral Res 2000;48(1):49-60
   PubMed Web of Science ®Google Scholar
• Bras AP, Sitar DS, Aoki FY. Comparative bioavailability of acyclovir from oral valacyclovir and acyclovir in patients treated for recurrent genital herpes simplex virus infection. Can J Clin Pharmacol 2001;8(4):207-11
   PubMedGoogle Scholar
• Evers DL, Komazin G, Ptak RG, Inhibition of human cytomegalovirus replication by benzimidazole nucleosides involves three distinct mechanisms. Antimicrob Agents Chemother 2004;48(10):3918-27
   PubMed Web of Science ®Google Scholar
• Thoma C, Borst E, Messerle M, Identification of the interaction domain of the small terminase subunit pUL89 with the large subunit pUL56 of human cytomegalovirus. Biochemistry 2006;45(29):8855-63
   PubMed Web of Science ®Google Scholar
• Reefschlaeger J, Bender W, Hallenberger S, Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action. J Antimicrob Chemother 2001;48(6):757-67
   PubMed Web of Science ®Google Scholar
• McSharry JJ, McDonough A, Olson B, Susceptibilities of human cytomegalovirus clinical isolates to BAY38-4766, BAY43-9695, and ganciclovir. Antimicrob Agents Chemother 2001;45(10):2925-7
   PubMed Web of Science ®Google Scholar
• Underwood MR, Ferris RG, Selleseth DW, Mechanism of action of the ribopyranoside benzimidazole GW275175X against human cytomegalovirus. Antimicrob Agents Chemother 2004;48(5):1647-51
   PubMed Web of Science ®Google Scholar
• Lischka P, Hewlett G, Wunberg T, In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother 2010;54(3):1290-7
   PubMed Web of Science ®Google Scholar
• Hwang JS, Kregler O, Schilf R, Identification of acetylated, tetrahalogenated benzimidazole D-ribonucleosides with enhanced activity against human cytomegalovirus. J Virol 2007;81(21):11604-11
   PubMed Web of Science ®Google Scholar
• Hwang JS, Schilf R, Drach JC, Susceptibilities of human cytomegalovirus clinical isolates and other herpesviruses to new acetylated, tetrahalogenated benzimidazole D-ribonucleosides. Antimicrob Agents Chemother 2009;53(12):5095-101
   PubMed Web of Science ®Google Scholar
• De Clercq E. Nucleoside analogues exerting antiviral activity through a non-nucleoside mechanism. Nucleosides Nucleotides Nucleic Acids 2004;23(1-2):457-70
   PubMed Web of Science ®Google Scholar
• Wiebusch L, Truss M, Hagemeier C. Inhibition of human cytomegalovirus replication by small interfering RNAs. J Gen Virol 2004;85(Pt 1):179-84
   PubMedGoogle Scholar
• Dunn W, Trang P, Khan U, RNase P-mediated inhibition of cytomegalovirus protease expression and viral DNA encapsidation by oligonucleotide external guide sequences. Proc Natl Acad Sci USA 2001;98(26):14831-6
   PubMed Web of Science ®Google Scholar
• Yang YH, Li H, Zhou T, Engineered external guide sequences are highly effective in inducing RNase P for inhibition of gene expression and replication of human cytomegalovirus. Nucleic Acids Res 2006;34(2):575-83
   PubMed Web of Science ®Google Scholar
• Bai Y, Trang P, Li H, Effective inhibition in animals of viral pathogenesis by a ribozyme derived from RNase P catalytic RNA. Proc Natl Acad Sci USA 2008;105(31):10919-24
   PubMed Web of Science ®Google Scholar
• Loregian A, Rigatti R, Murphy M, Inhibition of human cytomegalovirus DNA polymerase by C-terminal peptides from the UL54 subunit. J Virol 2003;77(15):8336-44
   PubMed Web of Science ®Google Scholar
• Loregian A, Coen DM. Selective anti-cytomegalovirus compounds discovered by screening for inhibitors of subunit interactions of the viral polymerase. Chem Biol 2006;13(2):191-200
   PubMed Web of Science ®Google Scholar
• Gebert S, Schmolke S, Sorg G, The UL84 protein of human cytomegalovirus acts as a transdominant inhibitor of immediate-early-mediated transactivation that is able to prevent viral replication. J Virol 1997;71(9):7048-60
   PubMed Web of Science ®Google Scholar
• Colletti KS, Xu Y, Cei SA, Human cytomegalovirus UL84 oligomerization and heterodimerization domains act as transdominant inhibitors of oriLyt-dependent DNA replication: evidence that IE2-UL84 and UL84-UL84 interactions are required for lytic DNA replication. J Virol 2004;78(17):9203-14
   PubMed Web of Science ®Google Scholar
• Kaiser N, Lischka P, Wagenknecht N, Inhibition of human cytomegalovirus replication via peptide aptamers directed against the nonconventional nuclear localization signal of the essential viral replication factor pUL84. J Virol 2009;83(22):11902-13
   PubMed Web of Science ®Google Scholar
• McGregor A, Choi KY, Schleiss MR. Guinea pig cytomegalovirus GP84 is a functional homolog of the human cytomegalovirus (HCMV) UL84 gene that can complement for the loss of UL84 in a chimeric HCMV. Virology 2011;410(1):76-87
   PubMed Web of Science ®Google Scholar
• English EP, Chumanov RS, Gellman SH, Rational development of beta-peptide inhibitors of human cytomegalovirus entry. J Biol Chem 2006;281(5):2661-7
   PubMed Web of Science ®Google Scholar
• Secrist JA III, Tiwari KN, Riordan JM, Synthesis and biological activity of 2'-deoxy-4'-thio pyrimidine nucleosides. J Med Chem 1991;34(8):2361-6
   PubMed Web of Science ®Google Scholar
• Nigro G, Adler SP, La Torre R, Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 2005;353(13):1350-62
   PubMed Web of Science ®Google Scholar
• Adler SP, Nigro G. Findings and conclusions from CMV hyperimmune globulin treatment trials. J Clin Virol 2009;46(Suppl 4):S54-7
   PubMedGoogle Scholar
• Cui X, McGregor A, Schleiss MR, Cloning the complete guinea pig cytomegalovirus genome as an infectious bacterial artificial chromosome with excisable origin of replication. J Virol Methods 2008a;149(2):231-9
   PubMed Web of Science ®Google Scholar
• Gerna G, Lilleri D, Rognoni V, Preemptive therapy for systemic and pulmonary human cytomegalovirus infection in lung transplant recipients. Am J Transplant 2009;9(5):1142-50
   PubMed Web of Science ®Google Scholar
• Chong AS, Zeng H, Knight DA, Concurrent antiviral and immunosuppressive activities of leflunomide in vivo. Am J Transplant 2006;6(1):69-75
   PubMed Web of Science ®Google Scholar
• Efferth T, Romero MR, Wolf DG, The antiviral activities of artemisinin and artesunate. Clin Infect Dis 2008;47(6):804-11
   PubMed Web of Science ®Google Scholar
• Demopoulos L, Polinsky M, Steele G, Reduced risk of cytomegalovirus infection in solid organ transplant recipients treated with sirolimus: a pooled analysis of clinical trials. Transplant Proc 2008;40(5):1407-10
   PubMed Web of Science ®Google Scholar
• Hill JA, Hummel M, Starling RC, A lower incidence of cytomegalovirus infection in de novo heart transplant recipients randomized to everolimus. Transplantation 2007;84(11):1436-42
   PubMed Web of Science ®Google Scholar
• Marty FM, Bryar J, Browne SK, Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: A cohort analysis. Blood 2007;110(2):490-500
   PubMed Web of Science ®Google Scholar
• Hansen SG, Strelow LI, Franchi DC, Complete sequence and genomic analysis of rhesus cytomegalovirus. J Virol 2003;77(12):6620-36
   PubMed Web of Science ®Google Scholar
• Rawlinson WD, Farrell HE, Barrell BG. Analysis of the complete DNA sequence of murine cytomegalovirus. J Virol 1996;70(12):8833-49
   PubMed Web of Science ®Google Scholar
• Schleiss MR, McGregor A, Choi KY, Analysis of the nucleotide sequence of the guinea pig cytomegalovirus (GPCMV) genome. Virol J 2008;5(1):139
   PubMedGoogle Scholar
• Vink C, Beuken E, Bruggeman CA. Complete DNA sequence of the rat cytomegalovirus genome. J Virol 2000;74(16):7656-65
   PubMed Web of Science ®Google Scholar
• Yamada S, Nozawa N, Katano H, Characterization of the guinea pig cytomegalovirus genome locus that encodes homologs of human cytomegalovirus major immediate-early genes, UL128, and UL130. Virology 2009;391(1):99-106
   PubMed Web of Science ®Google Scholar
• Cheng TP, Valentine MC, Gao J, Stability of murine cytomegalovirus genome after in vitro and in vivo passage. J Virol 2010;84(5):2623-8
   PubMed Web of Science ®Google Scholar
• Davison AJ, Dolan A, Akter P, The human cytomegalovirus genome revisited: Comparison with the chimpanzee cytomegalovirus genome. J Gen Virol 2003;84(Pt 1):17-28
   PubMedGoogle Scholar
• Rivailler P, Kaur A, Johnson RP, Genomic sequence of rhesus cytomegalovirus 180.92: Insights into the coding potential of rhesus cytomegalovirus. J Virol 2006;80(8):4179-82
   PubMed Web of Science ®Google Scholar
• Lilja AE, Shenk T. Efficient replication of rhesus cytomegalovirus variants in multiple rhesus and human cell types. Proc Natl Acad Sci USA 2008;105(50):19950-5
   PubMed Web of Science ®Google Scholar
• Oxford KL, Eberhardt MK, Yang KW, Protein coding content of the UL)b' region of wild-type rhesus cytomegalovirus. Virology 2008;373(1):181-8
   PubMed Web of Science ®Google Scholar
• Nozawa N, Yamamoto Y, Fukui Y, Identification of a 1.6 kb genome locus of guinea pig cytomegalovirus required for efficient viral growth in animals but not in cell culture. Virology 2008;379(1):45-54
   PubMed Web of Science ®Google Scholar
• Revello MG, Gerna G. Human cytomegalovirus tropism for endothelial/epithelial cells: Scientific background and clinical implications. Rev Med Virol 2010;20(3):136-55
   PubMed Web of Science ®Google Scholar
• Kern ER. Pivotal role of animal models in the development of new therapies for cytomegalovirus infections. Antiviral Res 2006;71(2-3):164-71
   PubMed Web of Science ®Google Scholar
• Redwood AJ, Messerle M, Harvey NL, Use of a murine cytomegalovirus K181-derived bacterial artificial chromosome as a vaccine vector for immunocontraception. J Virol 2005;79(5):2998-3008
   PubMed Web of Science ®Google Scholar
• Smith LM, McWhorter AR, Masters LL, Laboratory strains of murine cytomegalovirus are genetically similar to but phenotypically distinct from wild strains of virus. J Virol 2008;82(13):6689-96
   PubMed Web of Science ®Google Scholar
• Messerle M, Crnkovic I, Hammerschmidt W, Cloning and mutagenesis of a herpesvirus genome as an infectious bacterial artificial chromosome. Proc Natl Acad Sci USA 1997;94(26):14759-63
   PubMed Web of Science ®Google Scholar
• Voigt V, Forbes CA, Tonkin JN, Murine cytomegalovirus m157 mutation and variation leads to immune evasion of natural killer cells. Proc Natl Acad Sci USA 2003;100(23):13483-8
   PubMed Web of Science ®Google Scholar
• Lee SH, Zafer A, de Repentigny Y, Transgenic expression of the activating natural killer receptor Ly49H confers resistance to cytomegalovirus in genetically susceptible mice. J Exp Med 2003;197(4):515-26
   PubMed Web of Science ®Google Scholar
• Bubic I, Wagner M, Krmpotic A, Gain of virulence caused by loss of a gene in murine cytomegalovirus. J Virol 2004;78(14):7536-44
   PubMed Web of Science ®Google Scholar
• Smee DF, Morris JL, Leonhardt JA, Treatment of murine cytomegalovirus infections in severe combined immunodeficient mice with ganciclovir, (S)-1- [3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine, interferon, and bropirimine. Antimicrob Agents Chemother 1992;36(9):1837-42
   PubMed Web of Science ®Google Scholar
• Smee DF, Sugiyama ST, Reist EJ. Nucleotide analogs related to acyclovir and ganciclovir are effective against murine cytomegalovirus infections in BALB/c and severe combined immunodeficient mice. Antimicrob Agents Chemother 1994;38(9):2165-8
   PubMed Web of Science ®Google Scholar
• Bidanset DJ, Rybak RJ, Hartline CB, Replication of human cytomegalovirus in severe combined immunodeficient mice implanted with human retinal tissue. J Infect Dis 2001;184(2):192-5
   PubMed Web of Science ®Google Scholar
• DiLoreto D Jr, Epstein LG, Lazar ES, Cytomegalovirus infection of human retinal tissue: An in vivo model. Lab Invest 1994;71(1):141-8
   PubMed Web of Science ®Google Scholar
• Kern ER, Rybak RJ, Hartline CB, Predictive efficacy of SCID-hu mouse models for treatment of human cytomegalovirus infections. Antivir Chem Chemother 2001;12(Suppl 1):149-56
   PubMedGoogle Scholar
• Mocarski ES, Bonyhadi M, Salimi S, Human cytomegalovirus in a SCID-hu mouse: Thymic epithelial cells are prominent targets of viral replication. Proc Natl Acad Sci USA 1993;90(1):104-8
   PubMed Web of Science ®Google Scholar
• Bravo FJ, Cardin RD, Bernstein DI. A model of human cytomegalovirus infection in severe combined immunodeficient mice. Antiviral Res 2007;76(2):104-10
   PubMed Web of Science ®Google Scholar
• Rawlinson WD, Zeng F, Farrell HE, The murine cytomegalovirus (MCMV) homolog of the HCMV phosphotransferase (UL97(pk)) gene. Virology 1997;233(2):358-63
   PubMed Web of Science ®Google Scholar
• Wagner M, Michel D, Schaarschmidt P, Comparison between human cytomegalovirus pUL97 and murine cytomegalovirus (MCMV) pM97 expressed by MCMV and vaccinia virus: PM97 does not confer ganciclovir sensitivity. J Virol 2000;74(22):10729-36
   PubMed Web of Science ®Google Scholar
• Prichard MN, Gao N, Jairath S, A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency. J Virol 1999;73(7):5663-70
   PubMed Web of Science ®Google Scholar
• McGregor A, Choi KY, Cui X, Expression of the human cytomegalovirus UL97 gene in a chimeric guinea pig cytomegalovirus (GPCMV) results in viable virus with increased susceptibility to ganciclovir and maribavir. Antiviral Res 2008;78(3):250-9
   PubMed Web of Science ®Google Scholar
• McGregor A. Current and new cytomegalovirus antivirals and novel animal model strategies. Inflamm Allgery Drug Targets 2010;9(4):286-99
   PubMedGoogle Scholar
• Johnson KP. Mouse cytomegalovirus: placental infection. J Infect Dis 1969;120(4):445-50
   PubMed Web of Science ®Google Scholar
• Enders AC. A comparative study of the fine structure of the trophoblast in several hemochorial placentas. Am J Anat 1965;116:29-67
   PubMedGoogle Scholar
• Tsutsui Y. Developmental disorders of the mouse brain induced by murine cytomegalovirus: animal models for congenital cytomegalovirus infection. Pathol Int 1995;45(2):91-102
   PubMed Web of Science ®Google Scholar
• Cekinovic D, Golemac M, Pugel EP, Passive immunization reduces murine cytomegalovirus-induced brain pathology in newborn mice. J Virol 2008;82(24):12172-80
   PubMed Web of Science ®Google Scholar
• Mutnal MB, Cheeran MC, Hu S, Murine cytomegalovirus infection of neural stem cells alters neurogenesis in the developing brain. PLoS One 2011;6(1):e16211
   PubMedGoogle Scholar
• Tsutsui Y, Kosugi I, Kawasaki H, Roles of neural stem progenitor cells in cytomegalovirus infection of the brain in mouse models. Pathol Int 2008;58(5):257-67
   PubMed Web of Science ®Google Scholar
• Schachtele SJ, Mutnal MB, Schleiss MR, Cytomegalovirus-induced sensorineural hearing loss with persistent cochlear inflammation in neonatal mice. J Neurovirol 2011;17(3):201-11
   PubMed Web of Science ®Google Scholar
• Luker GD, Bardill JP, Prior JL, Noninvasive bioluminescence imaging of herpes simplex virus type 1 infection and therapy in living mice. J Virol 2002;76(23):12149-61
   PubMed Web of Science ®Google Scholar
• Klenovsek K, Weisel F, Schneider A, Protection from CMV infection in immunodeficient hosts by adoptive transfer of memory B cells. Blood 2007;110(9):3472-9
   PubMed Web of Science ®Google Scholar
• Yamada S, Kosugi I, Katano H, In vivo imaging assay for the convenient evaluation of antiviral compounds against cytomegalovirus in mice. Antiviral Res 2010;88(1):45-52
   PubMed Web of Science ®Google Scholar
• Tsutsui Y, Kawasaki H, Kosugi I. Reactivation of latent cytomegalovirus infection in mouse brain cells detected after transfer to brain slice cultures. J Virol 2002;76(14):7247-54
   PubMed Web of Science ®Google Scholar
• Lagenaur LA, Manning WC, Vieira J, Structure and function of the murine cytomegalovirus sgg1 gene: a determinant of viral growth in salivary gland acinar cells. J Virol 1994;68(12):7717-27
   PubMed Web of Science ®Google Scholar
• Barry PA, Strelow L. Development of breeding populations of rhesus macaques (macaca mulatta) that are specific pathogen-free for rhesus cytomegalovirus. Comp Med 2008;58(1):43-6
   PubMed Web of Science ®Google Scholar
• Swanson R, Bergquam E, Wong SW. Characterization of rhesus cytomegalovirus genes associated with anti-viral susceptibility. Virology 1998;240(2):338-48
   PubMed Web of Science ®Google Scholar
• North TW, Sequar G, Townsend LB, Rhesus cytomegalovirus is similar to human cytomegalovirus in susceptibility to benzimidazole nucleosides. Antimicrob Agents Chemother 2004;48(7):2760-5
   PubMed Web of Science ®Google Scholar
• Chang WL, Barry PA. Cloning of the full-length rhesus cytomegalovirus genome as an infectious and self-excisable bacterial artificial chromosome for analysis of viral pathogenesis. J Virol 2003;77(9):5073-83
   PubMed Web of Science ®Google Scholar
• Powers C, Fruh K. Rhesus CMV: an emerging animal model for human CMV. Med Microbiol Immunol 2008;197(2):109-15
   PubMed Web of Science ®Google Scholar
• Yue Y, Barry PA. Rhesus cytomegalovirus a nonhuman primate model for the study of human cytomegalovirus. Adv Virus Res 2008;72:207-26
   PubMed Web of Science ®Google Scholar
• Padilla-Carlin DJ, McMurray DN, Hickey AJ. The guinea pig as a model of infectious diseases. Comp Med 2008;58(4):324-40
   PubMed Web of Science ®Google Scholar
• Hickey AJ. Guinea pig model of infectious disease - viral infections. Curr Drug Targets 2011;112(7):1018-23
   Google Scholar
• Kaufmann P. Guinea pig cavia procellus. In: Benirschke K. editor. Comparitive placentation. Available from: http://medicine.ucsd.edu/cpa/guinea/htm 2004
   Google Scholar
• Kumar ML, Nankervis GA. Experimental congenital infection with cytomegalovirus: a guinea pig model. J Infect Dis 1978;138(5):650-4
   PubMed Web of Science ®Google Scholar
• Griffith BP, Hsiung GD. Cytomegalovirus infection in guinea pigs. IV. maternal infection at different stages of gestation. J Infect Dis 1980;141(6):787-93
   PubMed Web of Science ®Google Scholar
• Carter AM. Animal models of human placentation–a review. Placenta 2007;28(Suppl A):S41-7
   PubMed Web of Science ®Google Scholar
• Mess A. The guinea pig placenta: model of placental growth dynamics. Placenta 2007;28(8-9):812-15
   PubMed Web of Science ®Google Scholar
• Hartley JW, Rowe WP, Huebner RJ. Serial propagation of the guinea pig salivary gland virus in tissue culture. Proc Soc Exp Biol Med 1957;96(2):281-5
   PubMed Web of Science ®Google Scholar
• Aquino-de Jesus MJ, Griffith BP. Cytomegalovirus infection in immunocompromised guinea pigs: a model for testing antiviral agents in vivo. Antiviral Res 1989;12(4):181-93
   PubMed Web of Science ®Google Scholar
• Woolf NK, Koehrn FJ, Harris JP, Congenital cytomegalovirus labyrinthitis and sensorineural hearing loss in guinea pigs. J Infect Dis 1989;160(6):929-37
   PubMed Web of Science ®Google Scholar
• Woolf NK. Experimental congenital cytomegalovirus labyrinthitis and sensorineural hearing loss. Am J Otolaryngol 1990;11(5):299-303
   PubMed Web of Science ®Google Scholar
• Woolf NK, Harris JP, Ryan AF, Hearing loss in experimental cytomegalovirus infection of the guinea pig inner ear: prevention by systemic immunity. Ann Otol Rhinol Laryngol 1985;94(4 Pt 1):350-6
   PubMed Web of Science ®Google Scholar
• White DR, Choo DI, Stroup G, The effect of cidofovir on cytomegalovirus-induced hearing loss in a guinea pig model. Arch Otolaryngol Head Neck Surg 2006;132(6):608-15
   PubMed Web of Science ®Google Scholar
• Bourne N, Bravo FJ, Bernstein DI. Cyclic HPMPC is safe and effective against systemic guinea pig cytomegalovirus infection in immune compromised animals. Antiviral Res 2000;47(2):103-9
   PubMed Web of Science ®Google Scholar
• Bravo FJ, Cardin RD, Bernstein DI. Effect of maternal treatment with cyclic HPMPC in the guinea pig model of congenital cytomegalovirus infection. J Infect Dis 2006;193(4):591-7
   PubMed Web of Science ®Google Scholar
• Schleiss MR, Anderson JL, McGregor A. Cyclic cidofovir (cHPMPC) prevents congenital cytomegalovirus infection in a guinea pig model. Virol J 2006b;3:9
   PubMed Web of Science ®Google Scholar
• Parker S, Touchette E, Oberle C, Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model. Antiviral Res 2008;77(1):39-49
   PubMed Web of Science ®Google Scholar
• Toth K, Spencer JF, Dhar D, Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model. Proc Natl Acad Sci USA 2008;105(20):7293-7
   PubMed Web of Science ®Google Scholar
• Nixon DE, McVoy MA. Dramatic effects of 2-bromo-5,6-dichloro-1-beta-D-ribofuranosyl benzimidazole riboside on the genome structure, packaging, and egress of guinea pig cytomegalovirus. J Virol 2004;78(4):1623-35
   PubMed Web of Science ®Google Scholar
• Williams SL, Hartline CB, Kushner NL, In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses. Antimicrob Agents Chemother 2003;47(7):2186-92
   PubMed Web of Science ®Google Scholar
• Schleiss MR, Bernstein DI, McVoy MA, The non-nucleoside antiviral, BAY 38-4766, protects against cytomegalovirus (CMV) disease and mortality in immunocompromised guinea pigs. Antiviral Res 2005;65(1):35-43
   PubMed Web of Science ®Google Scholar
• Weber O, Bender W, Eckenberg P, Inhibition of murine cytomegalovirus and human cytomegalovirus by a novel non-nucleosidic compound in vivo. Antiviral Res 2001;49(3):179-89
   PubMed Web of Science ®Google Scholar
• Chatterjee A, Harrison CJ, Britt WJ, Modification of maternal and congenital cytomegalovirus infection by anti-glycoprotein b antibody transfer in guinea pigs. J Infect Dis 2001;183(11):1547-53
   PubMed Web of Science ®Google Scholar
• Bratcher DF, Bourne N, Bravo FJ, Effect of passive antibody on congenital cytomegalovirus infection in guinea pigs. J Infect Dis 1995;172(4):944-50
   PubMed Web of Science ®Google Scholar
• Britt WJ, Mach M. Human cytomegalovirus glycoproteins. Intervirology 1996;39(5-6):401-12
   PubMed Web of Science ®Google Scholar
• Gretch DR, Kari B, Gehrz RC, A multigene family encodes the human cytomegalovirus glycoprotein complex gcII (gp47-52 complex). J Virol 1988;62(6):1956-62
   PubMed Web of Science ®Google Scholar
• Huber MT, Compton T. The human cytomegalovirus UL74 gene encodes the third component of the glycoprotein H-glycoprotein L-containing envelope complex. J Virol 1998;72(10):8191-7
   PubMed Web of Science ®Google Scholar
• Britt WJ, Harrison C. Identification of an abundant disulfide-linked complex of glycoproteins in the envelope of guinea pig cytomegalovirus. Virology 1994;201(2):294-302
   PubMed Web of Science ®Google Scholar
• Schleiss MR, Bourne N, Stroup G, Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine. J Infect Dis 2004;189(8):1374-81
   PubMed Web of Science ®Google Scholar
• Hobom U, Brune W, Messerle M, Fast screening procedures for random transposon libraries of cloned herpesvirus genomes: mutational analysis of human cytomegalovirus envelope glycoprotein genes. J Virol 2000;74(17):7720-9
   PubMed Web of Science ®Google Scholar
• Fong CK, Cohen SD, McCormick S, Antiviral effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against cytomegalovirus infection in a guinea pig model. Antiviral Res 1987;7(1):11-23
   PubMed Web of Science ®Google Scholar
• Woolf NK, Ochi JW, Silva EJ, Ganciclovir prophylaxis for cochlear pathophysiology during experimental guinea pig cytomegalovirus labyrinthitis. Antimicrob Agents Chemother 1988;32(6):865-72
   PubMed Web of Science ®Google Scholar
• Fox DS, Schleiss MR. Sequence and transcriptional analysis of the guinea pig cytomegalovirus UL97 homolog. Virus Genes 1997;15(3):255-64
   PubMed Web of Science ®Google Scholar
• Chang MH, Cirillo SL, Cirillo JD. Using luciferase to image bacterial infections in mice. J Vis Exp 2011(48):2547
   PubMedGoogle Scholar
• Lischka P, Zimmermann H. Antiviral strategies to combat cytomegalovirus infections in transplant recipients. Curr Opin Pharmacol 2008;8(5):541-8
   PubMed Web of Science ®Google Scholar
• Sia IG, Patel R. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin Microbiol Rev 2000;13(1):83; 121, table of contents
   PubMed Web of Science ®Google Scholar
• Singh N. Optimization of outcomes related to cytomegalovirus in organ transplant recipients. Transplantation 2006;82(1):15-16
   PubMed Web of Science ®Google Scholar
• Singh N, Wagener MM. Strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2006;144(6):456; 7; author reply 457
   PubMed Web of Science ®Google Scholar
• Michel D and Mertens T. Antiviral intervention, resistance and perspectives. In: Matthias J. Reddhase editor. Cytomegaloviruses [Chapter 27]. Molecular biology and immunology. Caister Academic Press; Wymondham, Norfolk, UK: 2005. p. 573-90
   Google Scholar